Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Telomir Pharmaceuticals, Inc. Common Stock (TELO)
USD1.21
-0.03 (-2.42%)
US NASDAQ Healthcare Biotechnology
Address
855 N Wolfe Street 21205
Baltimore, FL, US
Baltimore, FL, US
CEO
Erez Aminov
Website
telomirpharma.com
IPO
2019-04-09
CIK 1971532 ISIN US87975F1049
Description
Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against various age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, and also to assist in recovery post-chemotherapy. It achieves this by disrupting and inhibiting inflammatory pathways that are triggered by interleukin-17. Established in 2021, the company was initially known as Metallo Therapies Inc., officially adopting the name Telomir Pharmaceuticals, Inc. on October 10, 2022. The company's headquarters are located in Baltimore, Maryland.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.21
-0.03 (-2.42%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
152.7K
Beta
-0.24
Float Shares
19.03M
Free Float %
55.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.25% | -4.51% | -3.05% | +16.51% | -5.93% | -4.51% | -52.26% | -81.86% | -81.86% | -81.86% | -81.86% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
1.21
DCF (Unlevered)
0.23
-81.0%
DCF (Levered)
0.23
-81.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2025-12 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
17.81
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+41.1% ★ Q1'26: +59.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+7.2% Q1'26: +15.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00×
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|
| Revenue |
—
|
—
est: 1.50B (-100.0%)
|
1.50M
1.50M – 1.50M
-99.9% YoY
|
| EBITDA |
48.0K
|
-10.54M
|
—
— – —
|
| EBIT |
-12.19M
|
-10.54M
|
—
— – —
|
| Net Income |
-16.53M
est: -16.54M (+0.1%)
|
-10.41M
est: -9.81M (-6.1%)
|
-8.86M
-8.86M – -8.86M
+9.7% YoY
|
| SGA |
9.64M
|
8.10M
|
—
— – —
|
| EPS |
-0.56
est: -0.56 (+0.0%)
|
-0.33
est: -0.31 (-6.5%)
|
-0.28
-0.28 – -0.28
+9.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
15
Total invested
1.79M
Insider transactions (90d)
1
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
15
-18 vs prev Q
New positions
4
Closed positions
22
Increased
6
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1.14M +35.7K (+3.2%) | 1.51M -18.6K (-1.2%) | 3.66% -0.007 pp | 0.00% +0.000 pp | USD6.01 -77.9% | 7 qtrs — |
| 2 | BLACKROCK, INC. | 285.5K -6.0K (-2.1%) | 379.7K -25.4K (-6.3%) | 0.92% -0.052 pp | 0.00% +0.000 pp | USD4.72 -71.8% | 6 qtrs — |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 223.5K +27.5K (+14.0%) | 297.5K +24.8K (+9.1%) | 0.72% +0.067 pp | 0.00% +0.000 pp | USD4.58 -71.0% | 7 qtrs — |
| 4 | MILLENNIUM MANAGEMENT LLC | 167.0K -55.4K (-24.9%) | 222.1K -87.1K (-28.2%) | 0.54% -0.203 pp | 0.00% +0.000 pp | USD1.25 +6.4% | 3 qtrs — |
| 5 | STATE STREET CORP | 58.6K +— (+0.0%) | 77.9K -3.5K (-4.3%) | 0.19% -0.007 pp | 0.00% +0.000 pp | USD4.40 -69.8% | 7 qtrs — |
| 6 | BANK OF NEW YORK MELLON CORP | 51.5K +— (+0.0%) | 68.4K -3.1K (-4.3%) | 0.17% -0.006 pp | 0.00% +0.000 pp | USD4.04 -67.1% | 7 qtrs — |
| 7 | SUNCOAST EQUITY MANAGEMENT | 51.2K +— (+0.0%) | 68.1K -3.1K (-4.3%) | 0.16% -0.006 pp | 0.01% 0.000 pp | USD5.96 -77.7% | 8 qtrs — |
| 8 | NORTHERN TRUST CORP | 41.8K +— (+0.0%) | 55.7K -2.5K (-4.3%) | 0.13% -0.005 pp | 0.00% +0.000 pp | USD4.83 -72.5% | 6 qtrs — |
| 9 | XTX TOPCO LTD | 39.7K +39.7K (+100.0%) | 52.8K +52.8K (+100.0%) | 0.13% +0.128 pp | 0.00% +0.001 pp | USD1.33 +0.0% | 1 qtrs NEW |
| 10 | PENSIONMARK FINANCIAL GROUP, LLC | 35.4K +35.4K (+100.0%) | 47.1K +47.1K (+100.0%) | 0.11% +0.114 pp | 0.00% +0.001 pp | USD1.33 +0.0% | 1 qtrs NEW |
| 11 | ADVISOR GROUP HOLDINGS, INC. | 33.8K +9.3K (+37.9%) | 44.9K +12.4K (+38.3%) | 0.11% +0.027 pp | 0.00% +0.000 pp | USD2.49 -46.6% | 8 qtrs — |
| 12 | RESOURCES INVESTMENT ADVISORS, LLC. | 23.0K +— (+0.0%) | 30.6K -1.4K (-4.3%) | 0.07% -0.003 pp | 0.00% +0.000 pp | USD1.30 +2.3% | 3 qtrs — |
| 13 | VIRTU FINANCIAL LLC | 14.3K +14.3K (+100.0%) | 19.0K +19.0K (+100.0%) | 0.05% +0.046 pp | 0.00% +0.001 pp | USD1.33 +0.0% | 1 qtrs NEW |
| 14 | UBS GROUP AG | 14.0K -49.5K (-77.9%) | 18.7K -69.6K (-78.8%) | 0.05% -0.167 pp | 0.00% +0.000 pp | USD1.98 -32.8% | 7 qtrs — |
| 15 | VESTMARK ADVISORY SOLUTIONS, INC. | 13.1K +13.1K (+100.0%) | 17.4K +17.4K (+100.0%) | 0.04% +0.042 pp | 0.00% +0.000 pp | USD1.33 +0.0% | 1 qtrs NEW |
| 16 | MORTON CAPITAL MANAGEMENT LLC/CA | 12.7K +12.7K (+100.0%) | 16.8K +16.8K (+100.0%) | 0.04% +0.041 pp | 0.00% +0.003 pp | USD1.33 +0.0% | 1 qtrs NEW |
| 17 | CLEARSTEAD ADVISORS, LLC | 12.5K +— (+0.0%) | 16.7K -752.0 (-4.3%) | 0.04% -0.001 pp | 0.00% +0.000 pp | USD1.39 -4.3% | 2 qtrs — |
| 18 | JANE STREET GROUP, LLC | 11.7K -8.1K (-41.0%) | 15.5K -12.0K (-43.5%) | 0.04% -0.028 pp | 0.00% +0.000 pp | USD1.25 +6.4% | 3 qtrs — |
| 19 | MARINER, LLC | 11.6K -8.4K (-41.8%) | 15.5K -12.3K (-44.3%) | 0.04% -0.029 pp | 0.00% +0.000 pp | USD1.39 -4.3% | 2 qtrs — |
| 20 | KESTRA PRIVATE WEALTH SERVICES, LLC | 11.0K +— (+0.0%) | 14.6K -660.0 (-4.3%) | 0.04% -0.001 pp | 0.00% +0.000 pp | USD1.39 -4.3% | 2 qtrs — |
| 21 | REGIONS FINANCIAL CORP | 10.6K +— (+0.0%) | 14.1K -638.0 (-4.3%) | 0.03% -0.001 pp | 0.00% +0.000 pp | USD1.39 -4.3% | 2 qtrs — |
| 22 | TWO SIGMA SECURITIES, LLC | 10.0K +10.0K (+100.0%) | 13.3K +13.3K (+100.0%) | 0.03% +0.032 pp | 0.00% +0.002 pp | USD1.33 +0.0% | 3 qtrs — |
| 23 | PRAETORIAN WEALTH MANAGEMENT, INC. | 10.0K -10.0K (-50.0%) | 13.3K -14.5K (-52.2%) | 0.03% -0.034 pp | 0.00% -0.003 pp | USD1.39 -4.3% | 2 qtrs — |
| 24 | IFP ADVISORS, INC | 3.0K +3.0K (+100.0%) | 4.0K +4.0K (+100.0%) | 0.01% +0.010 pp | 0.00% +0.000 pp | USD1.33 +0.0% | 1 qtrs NEW |
| 25 | FORTITUDE FAMILY OFFICE, LLC | 1.3K +1.3K (+100.0%) | 1.8K +1.8K (+100.0%) | 0.00% +0.004 pp | 0.00% +0.000 pp | USD1.33 +0.0% | 3 qtrs — |
| 26 | JONES FINANCIAL COMPANIES LLLP | 600.00 +— (+0.0%) | 798.00 -36.0 (-4.3%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.69 -50.6% | 6 qtrs — |
| 27 | EVERSOURCE WEALTH ADVISORS, LLC | 379.00 +— (+0.0%) | 504.00 -23.0 (-4.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.61 -17.4% | 4 qtrs — |
| 28 | BNP PARIBAS ARBITRAGE, SNC | 206.00 -141.0 (-40.6%) | 274.00 -208.0 (-43.2%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD5.51 -75.9% | 7 qtrs — |
| 29 | JPMORGAN CHASE & CO | 121.00 +121.0 (+100.0%) | 161.00 +161.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.32 +0.8% | 8 qtrs — |
| 30 | BANK OF AMERICA CORP /DE/ | 23.00 +— (+0.0%) | 30.00 -2.0 (-6.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.35 -69.4% | 7 qtrs — |
| 31 | SBI SECURITIES CO., LTD. | 4.00 +— (+0.0%) | 5.00 -1.0 (-16.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.25 -59.1% | 5 qtrs — |
| 32 | BARCLAYS PLC | 2.00 -7.0K (-100.0%) | 3.00 -45.1K (-100.0%) | 0.00% -0.023 pp | 0.00% +0.000 pp | USD2.50 -46.8% | 7 qtrs — |
| 33 | CITIGROUP INC | 1.00 +— (+0.0%) | 1.00 +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.00 -66.8% | 8 qtrs — |
| 34 | RAYMOND JAMES FINANCIAL INC | — -75.3K (-100.0%) | — -104.7K (-100.0%) | 0.00% -0.251 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 35 | MORGAN STANLEY | — -334.0 (-100.0%) | — -464.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 7 qtrs SOLD |
| 36 | QUBE RESEARCH & TECHNOLOGIES LTD | — -11.0K (-100.0%) | — -15.3K (-100.0%) | 0.00% -0.037 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 37 | GOLDMAN SACHS GROUP INC | — -22.6K (-100.0%) | — -31.5K (-100.0%) | 0.00% -0.075 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 38 | ROYAL BANK OF CANADA | — -599.0 (-100.0%) | — -1.0K (-100.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD— | 7 qtrs SOLD |
| 39 | SRS CAPITAL ADVISORS, INC. | — -9.0 (-100.0%) | — -12.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 40 | TOWER RESEARCH CAPITAL LLC (TRC) | — -1.3K (-100.0%) | — -1.7K (-100.0%) | 0.00% -0.004 pp | 0.00% +0.000 pp | USD— | 7 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 12 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.00% | 45.7K | 0.60% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 272.1K | 0.05% |
| 3 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 2.2K | 0.03% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 6.2K | 0.17% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 455.65 | 0.17% |
| 6 | Vanguard Total Stock Market ETF VTI | 0.00% | 1.05M | 0.03% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 2.3K | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.3K | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 507.92 | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 55.99 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
7.32M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+7,319,710
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-22 | Aminov Erez | Director / Officer | J-Other | A | Common Stock | 7,319,710 | 1.37 | 10.03M | 7,319,710 | D | ↗ |
| 2025-09-29 | MIRA PHARMACEUTICALS, INC. | 10% Owner | — | — | Common Stock, no par value | 0 | 0.00 | — | 3,521,127 | D | ↗ |
| 2025-05-28 | Aminov Erez | Director / Officer | A-Award | A | Restricted Stock Units (RSUs) | 400,000 | 0.00 | — | 400,000 | D | ↗ |
| 2025-05-15 | Weichselbaum Alan | Officer | — | — | Stock Options (right to buy) | 50,000 | 2.75 | 137.5K | 0 | D | ↗ |
| 2024-12-31 | Aminov Erez | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-11-21 | Bay Shore Trust | 10% Owner | G-Gift | D | Common Stock (right to buy) | 100,000 | 3.73 | 373.0K | 2,339,025 | I | ↗ |
| 2024-08-27 | Yanez Michelle | Officer | A-Award | A | Incentive Stock Options (right to buy) | 200,000 | 5.02 | 1.00M | 200,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
34.38M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
| Filing date | Form type | Filing |
|---|---|---|
| 2026-02-19 | DEFA14A | ↗ |
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Erez Aminov | Chairman of the Board & Chief Executive Officer | 318.6K | male |
| Alan Weichselbaum | Chief Financial Officer | 59.2K | male |
| Itzchak Angel | Chief Scientific Advisor | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TELO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
